July 08, 2020

Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for Surgery

RecommendThanks for recommending this page!

The page you recommended will be added to the "what others are reading" feed on "My ACR".

 BookmarkThanks for bookmarking this page!

The page you bookmarked will be added to the "my reading list" feed on "My ACR".

NRG Oncology opened a Phase I trial (NRG-GI007) examining the safety of combining the administration of the viral agent Telomelysin during endoscopy, with chemoradiation for patients with advanced esophageal cancer who are not candidates for surgery.

Read the study